The United States Patent and Trademark Office has issued a method of treatment patent to Aradigm for its inhaled nicotine formulations. US Patent No. 8,256,433, for Systems and Methods for Effecting Cessation of Tobacco Use, provide exclusivity for the systems until January 7, 2024.
Aradigm President and CEO Igor Gonda commented, “Tobacco smoking remains an enormous healthcare problem in the US, which we believe is entirely preventable. The craving for cigarettes has been documented to be a key factor causing the high failure rate of currently approved pharmaceutical approaches to smoking cessation. Several key opinion leaders believe that the ideal smoking cessation tool should emulate the delivery of nicotine by cigarettes – i.e., a true lung delivery that provides a very rapid uptake of nicotine into the arterial blood similar to that resulting from smoking cigarettes. Aradigm has developed the AERX Nicotine Inhaler, an inhalation system which addresses this critical product attribute and, in contrast to cigarettes, delivers pure nicotine dissolved in water.”
US patents 6,799,576 and 6,874,507 regarding smoking cessation systems already provided exclusivity until 2019. According to the company, “The new patent extends the coverage to containers with novel features anticipated to provide additional smoking cessation benefits.”
Read the Aradigm press release.
View US Patent No. 8,256,433.
